Hormone therapy and breast cancer: what 20 years of data show, by type and timing

The question: is hormone therapy safe for my breasts?

The 2002 Women's Health Initiative (WHI) headlines left a fear that has lasted two decades. Blanket reassurance since then hasn't settled it either. The answer isn't one yes or no, because it changes with three things. The first is whether you take estrogen alone or estrogen plus a progestogen (a progesterone-like drug that protects the uterine lining). The second is how long you use it. The third is which progestogen it is.

One caveat frames everything below: most of the evidence comes from postmenopausal women. WHI enrolled women aged 50 to 79, averaging about 63¹. The largest observational analysis included only postmenopausal women². How well that applies to someone starting in her late 40s or early 50s is a real question.

What did the big trials find about estrogen alone versus estrogen plus progestin?

WHI ran two randomized trials. Women who had had a hysterectomy took estrogen alone (conjugated equine estrogen, or CEE) or placebo. Women with a uterus took CEE plus a synthetic progestin, medroxyprogesterone acetate (MPA), or placebo. Over 20 years of follow-up in 27,347 women, the two arms went in opposite directions¹.

Estrogen alone was linked to fewer breast cancers: 238 versus 296 on placebo, a hazard ratio (HR) of 0.78, meaning roughly 22% lower. Breast cancer mortality was also lower (HR 0.60). Estrogen plus MPA was linked to more: 584 versus 447 cases, an HR of 1.28, or roughly 28% higher. There was no significant difference in breast cancer deaths¹.

The added risk from combined therapy lasted for many years. The Cochrane review of placebo-controlled trials agrees. It concluded that continuous combined therapy probably increases risk³. The result for estrogen alone is not strong enough to rule out that it has no effect on breast cancer³.

Two limits matter. WHI tested only oral CEE and MPA, so the results may not transfer to estradiol, patches or micronized progesterone. Many women in both groups stopped taking the study drug before the trial ended.

The combined-therapy arm of WHI was stopped early, in 2002, after an average of about 5.2 years⁵. Invasive breast cancer had crossed a pre-set safety boundary, and overall risks were judged to outweigh benefits. In absolute terms, the original report estimated about 8 extra invasive breast cancers per 10,000 women per year of combined therapy⁵.

Why do the observational studies tell a different story?

Large observational studies don't match WHI on estrogen alone. The 2019 Lancet analysis pooled 108,647 postmenopausal breast cancers. After 5 to 14 years of current use, it found an RR of about 1.33 for estrogen alone and 2.08 for combined therapy². It also found excess in years 1 to 4 (RR 1.17 and 1.60²). Whether that early excess is real or reflects screening or user differences is unclear.

Trial authors say their findings in women in their fifties broadly match the observational research, with one exception for breast cancer with estrogen alone. A separate reappraisal argues that estrogen alone shows long-term benefit in that age group. It cautions that subgroup analyses are not a sound basis for guidelines. Proposed explanations include the hysterectomy population, prior hormone use, and whether oral CEE results generalize. None is proven.

Duration matters in the observational data. Shorter use of systemic estradiol shows no added risk, but longer use is linked to added risk.

What does this look like in actual numbers?

Relative risks sound alarming and hide small baselines. The Lancet authors illustrate it this way, assuming the associations are causal². For average-weight women in developed countries, five years of therapy starting at age 50 raises breast cancer incidence at ages 50 to 69 by about 1 in 50 users of estrogen plus daily progestogen, 1 in 70 for estrogen plus intermittent progestogen, and 1 in 200 for estrogen alone².

The Menopause Society puts the added risk lower, at very few extra cases per 1,000 women over several years of use. The British Menopause Society concludes the absolute added risk is small whichever dataset is used, and most women using hormone therapy will not develop breast cancer because of it.

NICE says risk with estrogen-only therapy is very little or not increased. It says combined therapy carries a very small increase in the risk of dying from breast cancer⁴.

Does the type of progestogen, the route or the starting age change the picture?

Large cohort research suggests estrogen plus micronized progesterone carries no added risk, while some synthetic progestagens appear to carry higher risk. Other research found no clear added risk for micronized progesterone, though the uncertainty around that finding was considerable. Micronized progesterone doesn't appear to stimulate breast cell proliferation the way MPA does, though experts note that very few micronized progesterone users were included in the major analyses. This isn't settled.

Route. Oral and transdermal show no clear difference. Evidence reviews call the data insufficient to say transdermal estrogen is safer for breast cancer.

Starting age. The Lancet analysis found little difference in absolute excess for 5 years of use begun at 45, 50 or 55. Data for starting at 60 to 69 are sparse². Combined therapy started close to menopause appears to raise risk, even with short-term use. Recent reviews of trials in younger women found no demonstrated benefit for heart disease, cancer, depression or cognition, challenging the broad "timing hypothesis. It looked at benefits, not breast cancer risk.

After stopping. Regulators note that some added risk can persist for many years.

What don't we know yet?

No randomized breast cancer data exist for estradiol, patches or micronized progesterone, the regimens now most prescribed. That evidence is observational, with wide confidence intervals.

Direct evidence for women starting while still cycling, in early perimenopause, is thin.

Experts also disagree on framing. The Menopause Society calls the risk low but says it cannot definitively rule out that estrogen-containing therapy raises it. Short-term combined therapy is another dispute. The Society says risk does not increase appreciably, while the Lancet analysis found excess in years 1 to 4².

When should you talk to your doctor?

Bring your baseline risk: family history, breast density, BRCA status. The Menopause Society says therapy does not appear to raise risk further in women with a family history of breast cancer, or BRCA carriers who have had their ovaries removed, based largely on observational data. NICE notes risk varies with each person's risk factors⁴.

Useful questions are which regimen, which progestogen, how long, and when you'll reassess. Keep up routine screening. A new breast lump, nipple change or skin change while on therapy needs prompt evaluation. A previous breast cancer diagnosis is a separate conversation with its own guidance.

For most healthy symptomatic women under 60 and within 10 years of menopause, the Menopause Society says benefits outweigh risks.

This article is general information, not medical advice. Decisions about hormone therapy belong in a conversation with a clinician who knows your history.